Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

Acute myeloid leukemia (AML) is a myeloid malignancy carrying a heterogeneous molecular panel of mutations participating in the blockade of differentiation and the increased proliferation of myeloid hematopoietic stem and progenitor cells. The historical “3 + 7” treatment (cytara...

Full description

Bibliographic Details
Main Authors: Solène Fernandez, Vanessa Desplat, Arnaud Villacreces, Amélie V. Guitart, Noël Milpied, Arnaud Pigneux, Isabelle Vigon, Jean-Max Pasquet, Pierre-Yves Dumas
Format: Article
Language:English
Published: MDPI AG 2019-07-01
Series:International Journal of Molecular Sciences
Subjects:
acute myeloid leukemia
tyrosine kinase
inhibitors
targeted therapy
Online Access:https://www.mdpi.com/1422-0067/20/14/3429

Internet

https://www.mdpi.com/1422-0067/20/14/3429

Similar Items